By Ed Coghlan.
First of all, let me wish all of you Happy Father’s Day.
As a father, and now a grandfather, I’m very much humbled by my family and how they have positively influenced my life. I hope that each of you enjoy this day.
For the chronic pain community, there is a very important opportunity. That is to tell the FDA some important things.
As chronic pain advocate, Terri Lewis Ph.D. said “in recent years, federal agencies (FDA, CDC, DEA and more) have become increasingly concerned about the abuse and misuse of opioid products, which have been described as an epidemic of major proportions in certain parts of the United States. We know that the failure to properly account for legal, therapeutic uses and consequences versus the consequences of illicit use has created an enormous backlash for patients who rely on these medications and who have used them safely and properly to good effect.”
There will be a public meeting for patient-focused drug development on chronic pain at the United States Food and Drug Administration on Monday, July 9, 2018.
If you want to participate in a survey that will be presented to the FDA, we ask you to participate. The deadline for the National Pain Report readers is to fill this survey by midnight on Father’s Day.
Here’s the link to the survey:
Thus far, nearly 1500 people have already responded which Dr. Lewis will consolidate and submit to the FDA.
Many of our readers are wondering what the results are thus far, and Dr. Lewis indicated that a number of questions have surfaced from the survey.
1. Who are persons with multiple chronic comorbid conditions? What are their characteristics? What should we learn?
2. What drugs and interventions have they experienced? What works, what doesn’t?
3. What are the relationships within questions 1 and 2? How do these relationships correlate with other published data?
4. Given the relationships, what are the identifiable factors that lead to improved quality of life?
5. What are the barriers to care that are important for policy makers to understand?
The National Pain Report, which has aggressively promoted this survey, will report Dr. Lewis’ findings in advance of the FDA July 9 meeting.
To follow us on Twitter @natpainreport.
To follow the author on Twitter @edcoghlan
To follow Dr. Lewis on Twitter @tal7291